

Raymond James Institutional Investors Conference

Orlando, FL | March 7, 2023

Safe Harbor

- Some of the statements made in this presentation constitute forward-looking statements within the meaning of the
 Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements that address future
 results or occurrences. In some cases, you can identify forward-looking statements by terminology such as "may,"
 "might", "will", "should," "could" or the negative thereof. Generally, the words "anticipate", "believe", "continues", "expect",
 "intend", "estimate", "project", "plan" and similar expressions identify forward-looking statements. In particular, statements
 about our expectations, beliefs, plans, objectives, assumptions or future events or performance contained in this are
 forward-looking statements.
- We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors, many of which are outside of our control, which could cause our actual results, performance or achievements to differ materially from any results, performance or achievements expressed or implied by such forward-looking statements.
- Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. Additional risks and uncertainties are described more fully in "Risk Factors" in our periodic reports and other filings with the Securities and Exchange Commission. These forward-looking statements are made only as of the date of this presentation. We do not undertake and specifically decline any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.



Acadia is the leader in Behavioral Health in a moment of unparalleled need in the country

#1 Pure-play Behavioral Health (BH) provider in the US

75k Patients treated daily across our 4 service lines

250 Facilities across the nation

StrongPositioned to serve the large unmet needs in the country:foundationcommitment to clinical excellence, integration across thefor growthcontinuum of care and strong financial performance



National footprint and scale with regional density



Strong regional density across large parts of the country, generating strategic and revenue upside

~\$2.6B in 2022 Revenue across 250 facilities

Acute – 52 facilities

Stabilize and treat individuals who are at high risk of imminent danger to themselves or others in inpatient facilities

Specialty services – 37 facilities

Treat substance use, eating disorders, or co-occurring disorders in inpatient, residential, partial hospitalization, intensive outpatient, and outpatient settings

Comprehensive Treatment Centers (CTCs) – 151 facilities

Treat opioid use disorder (OUD) with medication and therapy in outpatient setting


Residential Treatment Centers (RTCs) – 10 facilities

Treat children and adolescents with behavioral health disorders in a non-hospital setting



1. Total revenue YE 12/31/22

Acadia is focused on complex mental health and substance use, a \$100B market with multiple strong tailwinds



1. Includes IP, residential, PHP (Partial Hospitalization Program)/IOP (Intensive Outpatient Program) as well as outpatient treatment of schizophrenia, bipolar disorder, and suicidality; 2. Analyses based on 3rd-party 2021 claims data (Medicare LD, DRG, SAMHSA 2021, Truven); 3. Analyses based on 3rd-party 2018-21 claims data (Medicare LD, DRG, SAMHSA 2021, Truven); 4. Estimates triangulated with: IHME forecasts of disease prevalence across BH condition categories; expert interviews; claims analyses; market trends; 5. SAMHSA Results from 2020 National Survey; Based on most cited estimate of psychiatric bed needs (50 per 100k pop.; JAMA 2022); 6. Based on most cited estimate of psychiatric bed need in the US which is 50 beds per 100k (Treatment Advocacy Center, 2008; JAMA Psychiatry, 2022); American Hospital Association Annual Survey, 2011-20 7. CDC's National Center for Health Statistics



Our strategy is to become the indispensable behavioral health provider for high-acuity and complex needs patient populations

Our core strategic priorities



Fuel facility growth through accelerated JV partnerships and de novo builds and launching programmatic M&A



Accelerate expansion across the care continuum, particularly for patients with opioid use and other substance use disorders



Strengthen capabilities and selectively leverage technology to increase access, improve care delivery and increase clinical integration



On December 7th, we laid out our clear path to continue our strong organic revenue and EBITDA trajectory in the near-to-long-term

	Near-term growth (2023)	Mid- to long-term growth (2024-28)
EBITDA growth	~10% Estimated EBITDA growth	10-12% Estimated annual EBITDA growth
Key investments to fuel go-forward growth	 Investments in the expansion of our existing facilities, primarily through bed additions (~300 beds per year) Expansion in high-need markets through de novo and JV facilities Ongoing focus on operational efficiencies and cost-management 	 Continued investments in the expansion of our existing facilities, primarily through bed additions Accelerated de novos, JV facilities and facility expansions (1,000+ beds per year) Expanded focus on substance use disorder (SUD) for increased de novo opportunities in attractive markets Stronger foundational improvements through select investments in our infrastructure (e.g., technology infrastructure, analytics, automation, care navigation)



Confidence in our outlook for 2023 and beyond

	Organic volume growth	 Accelerating volume growth (4% to 6%) and record census achieved in Q1 2023
к↑л ←O→ ⊻↓У	Growth strategy	 Strong trajectory across all 5 pathways: facility expansions, JVs, de novos, M&A and extension of the continuum of care
	Revenue per patient day	 Continued increases in revenue per day underpinned by continued strong payer relationships and robust demand
	Labor costs	 Wage inflation of 7% to 8% in 1H 2023 reflecting merit increases Moderation expected in 2H 2023 Internal recruiting/retention trending positively Premium pay peaked in Q3 2022





Raymond James Institutional Investors Conference

Orlando, FL | March 7, 2023